NPS Pharmaceuticals (NPSP) Misses Q3 EPS by 3c

NPS Pharmaceuticals (NASDAQ: NPSP) reported Q3 EPS of ($0.02), $0.03 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $57.2 million versus the consensus estimate of $59.5 million.

For earnings history and earnings-related data on NPS Pharmaceuticals (NPSP) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Range Resources (RRC) Tops Q1 EPS by 11c; offers production guidance
• WesBanco (WSBC) Tops Q1 EPS by 1c